Skip to content

Study · Animal study (in vivo) · rat · 2005

5 results

[Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages].

Timofeeva NM, Khavinson VKh, Malinin VV, Nikitina AA, Egorova VV

Advances in gerontology = Uspekhi gerontologii1 Jan 2005Cited by 1 (Europe PMC)

PMID16075683 (opens in a new tab)PepBankPUB-16075683
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In young rats, oral Livagen reduced digestive enzyme activity after two weeks.

    In plain wordsIn rats, oral Livagen reduced digestive enzyme activity in young animals after two weeks.

    Peptide
    Livagen (KEDA)
    Outcome
    DecreaseDigestive enzyme activity in young rats
    Study

    ratn: not reported in source

    young rats
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated · per os · two weeksAs given in this study (rat).

    Source sentences

    Summary
    After two weeks of Livagen administration per os in rats the digestive enzymes activity in young animals reduces, while in old animals it increases.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In old rats, oral Livagen increased digestive enzyme activity toward young control levels in most cases.

    In plain wordsIn rats, Livagen increased digestive enzyme activity in old animals toward young control levels in most cases.

    Peptide
    Livagen (KEDA)
    Outcome
    IncreaseDigestive enzyme activity in old rats
    Study

    ratn: not reported in source

    old rats
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated · per os · two weeksAs given in this study (rat).

    Source sentences

    Summary
    After two weeks of Livagen administration per os in rats the digestive enzymes activity in young animals reduces, while in old animals it increases.
    1 context sentence
    Summary · context
    It should be mentioned that the activity of enzymes in old rats after Livagen administration in the majority of cases approaches to the level of the activity in young animals of control group.
  3. 03LabIn vitro (cell-free)Activity measurement

    In vitro, Livagen reduced small-intestinal glycil-L-leucinedipeptidase activity by 50%.

    In plain wordsIn lab tests, Livagen reduced the activity of a small-intestinal enzyme by 50%.

    Peptide
    Livagen (KEDA)
    Outcome
    DecreaseGlycil-L-leucinedipeptidase activity
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Activity reduction
    50%
    small-intestinal glycil-L-leucinedipeptidase

    Source sentences

    Summary
    Under in vitro conditions Livagen reduces glycil-L-leucinedipeptidase activity in small intestine by 50%.

Studies that did not test the peptide alone2

In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Livagen (KEDA).

  1. 04LabNot a test of Livagen (KEDA) aloneIn vitro (cell-free)Pharmacokinetics

    In lab tests, Livagen was weakly hydrolyzed.

    In plain wordsIn lab tests, Livagen was weakly broken down.

    Peptide
    Livagen (KEDA)
    Outcome
    Direction not reportedPeptide hydrolysis
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    It is stated that Livagen (Lys-Glu-Asp-Ala) is a weakly hydrolyzed peptide.

    In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).

  2. 05LabNot a test of Livagen (KEDA) aloneIn vitro (cell-free)Pharmacokinetics

    In lab tests, small-intestinal peptide hydrolases did not hydrolyze Livagen.

    In plain wordsIn lab tests, small-intestinal peptide hydrolases did not break down Livagen.

    Peptide
    Livagen (KEDA)
    Outcome
    No significant changeHydrolysis by small-intestinal peptide hydrolases
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Gastrointestinal

    Source sentences

    Summary
    Peptide hydrolases of small intestine do not hydrolyze Livagen even to a small extent.

    In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.